Lamisil News
Anti-fungal tablet linked to liver deaths - Melbourne Herald Sun
The Therapeutic Goods Administration (TGA) has issued a warning about serious adverse side effects reported with oral Lamisil, a pill formulation for ...
Novartis optimistic despite Glivec setback - Business Standard
Part of the problem has been the intense competition from generic drug companies in the US, where sales of Lotrel (cardiac drug) and Lamisil (anti-fungal ...
Novartis optimistic despite Glivec setback - Business Standard
Part of the problem has been the intense competition from generic drug companies in the US, where sales of Lotrel (cardiac drug) and Lamisil (anti-fungal ...
European Stocks Pare Gains; Rio, Anglo American, Novartis Fall - Bloomberg
... fourth-quarter profit that missed analysts' estimates because of generic competition to the Lotrel heart medicine and the Lamisil antifungal treatment. ...
Novartis Profit Falls as Drugs Lose Sales to Generics (Update6) - Bloomberg
Sales of Lotrel fell 75 percent to $88 million, while the Lamisil antifungal medication dropped 71 percent to $66 million. Revenue from Trileptal for ...
Novartis Q4 hit by restructuring, weak US pharma sales; new share ... - CNNMoney.com
... due to generic competition for four products -- Lotrel, Lamisil, Trileptal and Famvir -- and the suspension of irritable bowel syndrome drug Zelnorm. ...
European Stocks Pare Gains; Rio, Anglo American, Novartis Fall - Bloomberg
... fourth-quarter profit that missed analysts' estimates because of generic competition to the Lotrel heart medicine and the Lamisil antifungal treatment. ...
Retailers, banks pace European share gains - MarketWatch
US pharmaceutical sales fell 21% in the quarter due to generic competition for four products - Lotrel, Lamisil, Trileptal and Famvir - and the suspension of ...
Novartis launches initiative with 2500 job losses - In-PharmaTechnologist.com
... has been affected by generic competition - Lotrel (amlodipine and benazepril) sales were down 34 per cent, Lamisil (terbinafine) sales down 31 per cent, ...
Fitch Publishes Third Quarter Global Pharmaceutical R&D Pipeline ... - PharmaLive.com (press release)
... generic competition for major products in the third quarter was limited to European names and mainly hit GlaxoSmithKline's Coreg and Novartis' Lamisil. ...
Lamisil RSS Feed